Advancing the Biosimilar Approval Framework: A Shift Towards Analytical Comparability
Below we highlight how the European Medicines Agency (EMA) is reshaping the biosimilar approval framework by prioritising advanced analytical characterisation over traditional comparative efficacy studies.
A recently finalized reflection paper outlines a science-based, tailored clinical development approach for biosimilars. For well-characterised biological molecules, the EMA now considers that a conclusion of high analytical similarity — supported by comparable pharmacokinetics (PK) — is sufficient to infer similar clinical efficacy and safety. This marks a major evolution in the biosimilar approval framework, reducing unnecessary clinical trial burdens while upholding rigorous standards.
Structure Determines Function: Quality Comparability as the Foundation
The paper reaffirms that biological medicines are inherently variable, yet minor differences in quality attributes are often clinically irrelevant if they do not impact safety or efficacy. Building on the ICH Q5E paradigm, it stresses the need to identify critical quality attributes through risk assessment that incorporates the molecule’s mechanism of action.
Prerequisites for Waiving Comparative Efficacy Studies
Clear conditions must be met before waiving comparative efficacy studies. These include a thorough understanding of the mechanism of action, state-of-the-art orthogonal analytical methods, discriminatory functional assays, a validated commercial manufacturing process, and a prospectively defined similarity assessment plan. The EMA strongly recommends seeking early scientific advice from the CHMP.
Smart Batch Selection and Statistical Approaches for Similarity Assessment
The guidance recommends using at least six independent biosimilar batches manufactured at commercial scale, alongside 10–30 reference medicinal product batches to adequately capture variability. Analytical methods must be highly precise and preferably orthogonal, with results presented both in tables and graphically. Differences falling outside similarity ranges do not automatically disqualify a candidate but require robust scientific justification.
Clinical Requirements Reduced to PK, Safety and Immunogenicity
Regulatory experience shows that comparative efficacy studies have rarely changed biosimilarity conclusions when analytical similarity is robust. As a result, they are no longer expected for well-characterised molecules. Comparative PK studies remain essential to confirm equivalent exposure, while safety and immunogenicity data can be collected descriptively within the same studies.
Economic Impact: Faster Development, Greater Competition, Lower Costs
By streamlining the biosimilar approval framework, development costs and timelines are expected to decrease significantly. This should accelerate market entry, intensify competition, and deliver greater price erosion for high-cost biologics. It may lead to increased focus on real-world evidence, switching data, and long-term economic outcomes rather than repeating clinical equivalence trials.
For the full reflection paper, refer to the EMA’s official document on the tailored clinical approach for biosimilar development.
Overall, this update represents a significant step toward more efficient and scientifically aligned regulation of biosimilar medicines.
